Last reviewed 2026-05-15 · How we verify

[11C]-GSK2256098 500 MBq

GlaxoSmithKline · Phase 1 active Small molecule

[11C]-GSK2256098 500 MBq is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	[11C]-GSK2256098 500 MBq
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[11C]-GSK2256098 500 MBq CI brief — competitive landscape report
[11C]-GSK2256098 500 MBq updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about [11C]-GSK2256098 500 MBq

What is [11C]-GSK2256098 500 MBq?

[11C]-GSK2256098 500 MBq is a Small molecule drug developed by GlaxoSmithKline.

Who makes [11C]-GSK2256098 500 MBq?

[11C]-GSK2256098 500 MBq is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is [11C]-GSK2256098 500 MBq in?

[11C]-GSK2256098 500 MBq is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: [11C]-GSK2256098 500 MBq vs similar drugs
Pricing: [11C]-GSK2256098 500 MBq cost, discount & access